As a scientist and drug developer, my mission is to deliver value to patients and innovation to the marketplace. I develop strategy and drive transformational change by building high performance teams and uniting people to share a vision for shaping the future of healthcare. I am passionate about scientific discovery, improving the patient experience and delivering clinically meaningful solutions to real-world problems. I create value by translating science and technology into innovative products and practices to improve the lives of patients and ignite business growth. With a proven track record in leading biopharma organizations, my experience spans early- and late-stage drug development, pipeline strategy, registrational trial execution, drug launch, and AI powered precision medicine. Bridging strategy and deliberate execution to business outcomes, I consistently deliver accelerated pipeline growth and successfully lead teams to achieve growth, prioritize the patient needs with equity and inclusivity, and maintain focus in times of uncertainty. My roots in academic science were anchored in the Ras-Raf-MAPK pathway and led me, in 2004, to validate B-Raf as a therapeutic target in melanoma. In 2006, I joined the pharmaceutical sector and within a few years witnessed the impact of novel immune therapies on the lives of patients. Through the development and approval of Yervoy® we delivered the first cancer immunotherapy that would revolutionize cancer treatment paradigms and would enliven our hope for cancer cures. During the past decade, I contributed to the late-stage development and approval of the PD-L1 checkpoint inhibitor Imfinzi® and led numerous early-stage clinical programs designed to maximize the efficacy of checkpoint blockade through novel combinations or bring forward novel immunotherapy targets and therapeutic modalities, including CD3 and CD28 directed bispecific antibodies. As grateful as I am for the progress we made, I am deeply aware that most cancer patients treated in real-world practice do not experience their own personal cure. Making real progress in the coming decade will demand the integration of predictive technologies to improve drug development paradigms, a deliberate focus on precision medicine, and innovation strategies that meaningfully improve patient care. Mindful of this, together with my collaborators I founded GUIDE.MRD, a public private partnership that will advance our confidence in ctDNA diagnostic assays and aim to develop minimal residual disease (MRD) as a clinical decision tool for solid tumor malignancies.